Patents by Inventor Stuart Rich

Stuart Rich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
    Patent number: 11969424
    Abstract: This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: April 30, 2024
    Assignee: TENAX THERAPEUTICS, INC.
    Inventors: Stuart Rich, Douglas Randall, Douglas Hay
  • Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
    Patent number: 11701355
    Abstract: This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.
    Type: Grant
    Filed: November 18, 2022
    Date of Patent: July 18, 2023
    Assignee: TENAX THERAPEUTICS, INC.
    Inventors: Stuart Rich, Douglas Randall, Douglas Hay
  • LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)
    Publication number: 20230107461
    Abstract: This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.
    Type: Application
    Filed: November 18, 2022
    Publication date: April 6, 2023
    Applicant: Tenax Therapeutics, Inc.
    Inventors: Stuart Rich, Douglas Randall, Douglas Hay
  • Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
    Patent number: 11607412
    Abstract: This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: March 21, 2023
    Assignee: TENAX THERAPEUTICS INC.
    Inventors: Stuart Rich, Douglas Randall, Douglas Hay
  • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION
    Publication number: 20210154193
    Abstract: The present disclosure pertains to the use of Imatinib or a pharmaceutically acceptable salt thereof for the treatment of pulmonary hypertension. A patient status relative to their baseline status of at least one of a proteomic biomarker, a protein biomarker, a transcriptomic biomarker, a patient specific genetic signature, an RNA expression biomarker signature, or a timed walk distance may be used in adjusting at least one of a dosage of imatinib or a treatment duration.
    Type: Application
    Filed: November 23, 2020
    Publication date: May 27, 2021
    Inventors: Anna R. Hemnes, Stuart Rich
  • TREPROSTINIL TREATMENT FOR INTERSTITIAL LUNG DISEASE AND ASTHMA
    Publication number: 20140018431
    Abstract: The present invention describes methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of interstitial lung disease or asthma, or a condition, such as pulmonary fibrosis, associated with interstitial lung disease or a condition associated with asthma. The invention also relates to kits for treatment and/or prevention of such condition that include an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 18, 2013
    Publication date: January 16, 2014
    Applicant: United Therapeutics Corporation
    Inventors: Michael Wade, Stuart Rich, Eugene Sullivan, Robert Roscigno, Roger Jeffs
  • TREPROSTINIL TREATMENT FOR INTERSTITIAL LUNG DISEASE AND ASTHMA
    Publication number: 20120129941
    Abstract: The present invention describes methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of interstitial lung disease or asthma, or a condition, such as pulmonary fibrosis, associated with interstitial lung disease or a condition associated with asthma. The invention also relates to kits for treatment and/or prevention of such condition that include an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 30, 2012
    Publication date: May 24, 2012
    Inventors: Michael Wade, Stuart Rich, Eugene Sullivan, Robert Roscigno, Roger Jeffs
  • TREPROSTINIL TREATMENT FOR INTERSTITIAL LUNG DISEASE AND ASTHMA
    Publication number: 20080280986
    Abstract: The present invention describes methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of interstitial lung disease or asthma, or a condition, such as pulmonary fibrosis, associated with interstitial lung disease or a condition associated with asthma. The invention also relates to kits for treatment and/or prevention of such condition that include an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 8, 2008
    Publication date: November 13, 2008
    Inventors: Michael Wade, Stuart Rich, Eugene Sullivan, Robert Roscigno, Roger Jeffs